Get the Stockscreener App
2.88
3.03%
-0.09
After Hours:
2.81
-0.07
-2.43%
C 4 Therapeutics Inc stock is traded at $2.88, with a volume of 2.14M.
It is down -3.03% in the last 24 hours and up +15.20% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
See More
Previous Close:
$2.97
Open:
$2.965
24h Volume:
2.14M
Relative Volume:
0.88
Market Cap:
$281.03M
Revenue:
$35.95M
Net Income/Loss:
$-104.99M
P/E Ratio:
-2.1228
EPS:
-1.3567
Net Cash Flow:
$-99.30M
1W Performance:
-1.37%
1M Performance:
+15.20%
6M Performance:
+17.55%
1Y Performance:
+78.88%
1-Day Range:
$2.77
$3.01
1-Week Range:
$2.77
$3.20
52-Week Range:
$1.21
$3.82
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.88 | 289.81M | 35.95M | -104.99M | -99.30M | -1.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Initiated | TD Cowen | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Equal-Weight |
| Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-13-23 | Upgrade | Stifel | Hold → Buy |
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics deepens Roche alliance to target breakthrough cancer therapies - MSN
CCCC (C4 Therapeutics Inc.) reports narrower than expected Q4 2025 loss, shares tick slightly higher in daily trading. - Cổng thông tin điện tử tỉnh Lào Cai
C4 Thera (CCCC) Stock Interest Rate (-2.88%) 2026-04-22Capital Preservation - UBND thành phố Hải Phòng
Wasatch holds 4.7% stake in C4 Therapeutics (CCCC) via Schedule 13G/A - Stock Titan
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Atrium offers stock awards to 7 new hires under Nasdaq rule - Stock Titan
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Grand Junction Daily Sentinel
Analysts see significant upside in C4 Therapeutics (CCCC) stock - MSN
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 19.4% - MarketBeat
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Eastern Progress
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 14, 2026 - BioSpace
Five new Travere hires get stock awards totaling 17,420 shares - Stock Titan
BridgeBio Oncology Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
CCCC Price Today: C4 Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
C4 Therapeutics Faces Ownership Changes Amidst Financial Declines - StocksToTrade
Travel Stocks: Can C4 Therapeutics Inc reach all time highs this year2026 Earnings & Safe Investment Capital Preservation Plans - baoquankhu1.vn
C4 Therapeutics Ownership Changes Raise Investor Concerns - timothysykes.com
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Amends By-laws to Designate Federal Courts as Exclusive Forum for Securities Act Claims - Minichart
C4 Therapeutics updates bylaws to designate federal courts as exclusive forums - Investing.com
C4 Therapeutics (NASDAQ: CCCC) narrows forums for securities lawsuits - Stock Titan
Roche and C4 Therapeutics to advance degrader-antibody conjugates research - Yahoo Finance
C4 yourself: $1B second Roche deal evidence of DAC faith - BioWorld News
What's Going On With C4 Therapeutics Stock Thursday?C4 Therapeutics (NASDAQ:CCCC) - Benzinga
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates - Investing News Network
C4 Therapeutics, Inc - Reuters
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion - marketscreener.com
C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates - Seeking Alpha
C4 Therapeutics and Roche Sign Over $1 Billion Collaboration to Develop Degrader-Antibody Conjugates for Cancer Treatment - Minichart
C4 Therapeutics Expands Roche Collaboration with New DAC Deal - TipRanks
C4 Therapeutics, Roche partner on cancer degrader conjugates By Investing.com - Investing.com India
C4 Therapeutics, Roche partner on cancer degrader conjugates - Investing.com
C4 Therapeutics (NASDAQ: CCCC) inks $1B+ DAC cancer deal with Roche - Stock Titan
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) - The Manila Times
Roche and C4 Therapeutics deepen collaboration to pursue novel cancer-targeting platforms - Traders Union
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement ... - Caledonian Record
C4 Therapeutics Expands Long-Term Partnership with Roche - GlobeNewswire
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):